Document Detail


Silencing of Notch3 Using shRNA driven by survivin promoter inhibits growth and promotes apoptosis of human T-cell acute lymphoblastic leukemia cells.
MedLine Citation:
PMID:  21940234     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: As a highly conserved system, the activation of the Notch pathway has been implicated in the tumorigenesis of various hematologic diseases, including leukemias, lymphomas, and multiple myeloma. The Notch3 receptor is frequently expressed in T-cell acute lymphoblastic leukemia (T-ALL).
METHODS: To explore its possibility as a therapeutic target for T-ALL, we investigated the effect of Notch3 silencing on Jurkat and SupT1 cells using a novel tumor-specific short hairpin RNA (shRNA) driven by survivin promoters.
RESULTS: We found that downregulated expression of Notch3 correlated with significant apoptosis and inhibition of proliferation.
CONCLUSION: These facts suggest that downregulating expression of Notch3 could attenuate the Notch signaling activity in T-ALL. All these results indicate that inhibition of Notch3 expression can result in potent antitumor activity in T-ALL.
Authors:
Jie Xiang; Yongri Ouyang; Ying Cui; Fang Lin; Jihong Ren; Min Long; Xi Chen; Junxia Wei; Huizhong Zhang; Huishong Zhang
Related Documents :
21615174 - Comparative proteomic analysis implicates commd proteins as epstein-barr virus targets ...
22080054 - Human erythema and matrix metalloproteinase-1 mrna induction, in vivo, share an action ...
21797124 - P16 and retinoblastoma protein expression in endometrial carcinoma and clinical signifi...
9387874 - In situ hybridization analysis of preprotachykinin-a and -b mrna levels in short-term s...
23826414 - Hyperbaric oxygen therapy provides neuroprotection following spinal cord injury in a ra...
20412594 - Hypoxia induces differential translation of enolase/mbp-1.
Publication Detail:
Type:  Journal Article     Date:  2011-09-21
Journal Detail:
Title:  Clinical lymphoma, myeloma & leukemia     Volume:  12     ISSN:  2152-2669     ISO Abbreviation:  Clin Lymphoma Myeloma Leuk     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-10     Completed Date:  2012-06-04     Revised Date:  2013-03-18    
Medline Journal Info:
Nlm Unique ID:  101525386     Medline TA:  Clin Lymphoma Myeloma Leuk     Country:  United States    
Other Details:
Languages:  eng     Pagination:  59-65     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Clinical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis*
Base Sequence
Blotting, Western
Cell Line, Tumor
Cell Proliferation*
Down-Regulation / genetics
Gene Expression Regulation, Leukemic
Humans
Inhibitor of Apoptosis Proteins / genetics*
Jurkat Cells
Molecular Sequence Data
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics,  pathology
Promoter Regions, Genetic / genetics*
RNA Interference
RNA, Small Interfering / genetics*
Receptors, Notch / genetics*
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction / genetics
Chemical
Reg. No./Substance:
0/BIRC5 protein, human; 0/Inhibitor of Apoptosis Proteins; 0/NOTCH3 protein, human; 0/RNA, Small Interfering; 0/Receptors, Notch
Comments/Corrections
Erratum In:
Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):97
Note: Zhang, Huishong [corrected to Zhang, Huizhong]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of an Educational Intervention on Caregivers' Beliefs About Infant Crying and Knowledge of Sh...
Next Document:  Cutaneous and Systemic Plasmacytosis vs. Cutaneous Plasmacytic Castleman Disease: Review and Specula...